TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD operating margin
Operating margin is operating income as a percentage of revenue.
TherapeuticsMD's operating margin for the twelve months ending Jun 30, 2026 was -120.9%. For fiscal 2025 it was -145.3%, against -347.1% the year before. The highest annual figure on record is 1.7% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -145.3% | +201.8 |
| FY2024 | Dec 31, 2024 | -347.1% | +307.5 |
| FY2023 | Dec 31, 2023 | -654.6% | −656.3 |
| FY2022 | Dec 31, 2022 | 1.7% | +3094.5 |
| FY2021 | Dec 31, 2021 | -3092.8% | −2853.0 |
| FY2020 | Dec 31, 2020 | -239.8% | +64.8 |
| FY2019 | Dec 31, 2019 | -304.6% | +504.3 |
| FY2018 | Dec 31, 2018 | -808.8% | −346.2 |
| FY2017 | Dec 31, 2017 | -462.7% | +3.6 |
| FY2016 | Dec 31, 2016 | -466.3% | −43.3 |
| FY2015 | Dec 31, 2015 | -422.9% | −63.3 |
| FY2014 | Dec 31, 2014 | -359.6% | −65.6 |
| FY2013 | Dec 31, 2013 | -294.1% | +128.9 |
| FY2012 | Dec 31, 2012 | -423.0% | −163.1 |
| FY2011 | Dec 31, 2011 | -259.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -93.9% | −20.9 |
| Q1 FY2026 | Mar 31, 2026 | -99.9% | +226.1 |
| Q4 FY2025 | Dec 31, 2025 | -173.8% | −76.0 |
| Q3 FY2025 | Sep 30, 2025 | -109.9% | +97.4 |
| Q2 FY2025 | Jun 30, 2025 | -73.0% | +1118.9 |
| Q1 FY2025 | Mar 31, 2025 | -326.0% | +38.9 |
| Q4 FY2024 | Dec 31, 2024 | -97.8% | +223.2 |
| Q3 FY2024 | Sep 30, 2024 | -207.3% | +358.4 |
| Q2 FY2024 | Jun 30, 2024 | -1191.9% | −550.8 |
| Q1 FY2024 | Mar 31, 2024 | -364.9% | −435.5 |
| Q4 FY2023 | Dec 31, 2023 | -320.9% | +3780.5 |
| Q2 FY2023 | Jun 30, 2023 | -565.7% | +3703.6 |
| Q1 FY2023 | Mar 31, 2023 | -641.1% | +1930.8 |
| Q4 FY2022 | Dec 31, 2022 | 70.7% | +260.1 |
| Q3 FY2022 | Sep 30, 2022 | -4101.4% | −3944.3 |
| Q2 FY2022 | Jun 30, 2022 | -4269.3% | −4116.3 |
| Q1 FY2022 | Mar 31, 2022 | -2571.9% | −2424.6 |
| Q4 FY2021 | Dec 31, 2021 | -189.5% | −36.2 |
| Q3 FY2021 | Sep 30, 2021 | -157.1% | −28.0 |
| Q2 FY2021 | Jun 30, 2021 | -152.9% | +267.9 |
| Q1 FY2021 | Mar 31, 2021 | -147.4% | +268.3 |
| Q4 FY2020 | Dec 31, 2020 | -153.3% | +125.9 |
| Q3 FY2020 | Sep 30, 2020 | -129.1% | −15.0 |
| Q2 FY2020 | Jun 30, 2020 | -420.9% | +264.1 |
| Q1 FY2020 | Mar 31, 2020 | -415.7% | +549.8 |
| Q4 FY2019 | Dec 31, 2019 | -279.2% | +469.9 |
| Q3 FY2019 | Sep 30, 2019 | -114.1% | +875.0 |
| Q2 FY2019 | Jun 30, 2019 | -684.9% | +192.6 |
| Q1 FY2019 | Mar 31, 2019 | -965.4% | −310.3 |
| Q4 FY2018 | Dec 31, 2018 | -749.1% | −223.5 |
| Q3 FY2018 | Sep 30, 2018 | -989.1% | −653.4 |
| Q2 FY2018 | Jun 30, 2018 | -877.5% | −411.0 |
| Q1 FY2018 | Mar 31, 2018 | -655.1% | −120.9 |
| Q4 FY2017 | Dec 31, 2017 | -525.6% | −14.3 |
| Q3 FY2017 | Sep 30, 2017 | -335.7% | +118.2 |
| Q2 FY2017 | Jun 30, 2017 | -466.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -534.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -511.3% | – |
| Q3 FY2016 | Sep 30, 2016 | -453.9% | – |
See a number that looks wrong?